• Oncolytics Biotech expects final GOBLET Cohort 4 results in fourth-quarter 2026; initial Cohort 5 results are expected in first-half 2027.
• Cohort 4 tests pelareorep with atezolizumab in anal cancer; Cohort 5 evaluates pelareorep-based combinations in previously untreated metastatic pancreatic cancer.
• Every fully enrolled cohort met its prespecified efficacy success criteria; survival in Cohort 4 exceeded expectations, while Cohort 5 outcomes continue maturing.
• Cohort 5 reporting could slip as patients remain under treatment or follow-up; findings will guide pelareorep’s development with checkpoint inhibitors.
• The final PanCAN grant payment is expected this quarter, with enrollment complete; broader study infrastructure is winding down while patient follow-up continues.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140930PRIMZONEFULLFEED9845215) on October 14, 2026, and is solely responsible for the information contained therein.